The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's ...

The race to supply obesity drugs is so competitive that one early-stage startup is already striking a deal for commercial ...

Kailera Therapeutics has launched into the increasingly crowded obesity space with a portfolio of assets acquired from China ...

Investors in weight-loss drug companies like Novo Nordisk and Eli Lilly face concerns over side effects and market ...

The FDA cleared a drug-free capsule for weight management in adults with a BMI of 25-40, said maker Epitomee Medical. Once ...

The company is also preparing for the potential market introduction of orforglipron, an oral obesity drug, which is expected to further alleviate capacity constraints. The analyst pointed out that ...

Scaling GLP-1 manufacturing capacity remains a key priority for the pharma industry, to help supply catch up with the ...

For those conducting R&D into developing a new form of weight loss therapy, the most obvious target is the development of an oral treatment. As such, there is a race by major obesity drug ...

We’re only a few months a way from the end of the year, but pharma companies still have a steady stream of clinical trial ...

Amgen (AMGN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Michael Yee from ...